Immunocore Holdings plc

XNASHealth care

Last traded price · USD

$29.23

+0.00%Delayed · Pre-market

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 16:00 IST · A quote does not mean the product is available to trade on your account.

Day's open: —
Previous close: $29.23
Volume: —
Day's high: —
Day's low: —

In brief

Immunocore Holdings plc is a health care company listed on Nasdaq, valued at about $1.51B.
Its shares closed at $29.23 on 4 Nov 2026, down 8.4% over the past year.
From India you can buy IMCR in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy Immunocore Holdings plc (IMCR) shares from India?

Yes. Indian residents can invest in the US stock market under the Reserve Bank of India's Liberalised Remittance Scheme (LRS), which lets a resident individual remit up to USD 250,000 per financial year, across all permitted purposes combined. US-listed stocks and ETFs are a permitted investment under the LRS. You are solely responsible for ensuring your remittances comply with the LRS annual limit, the applicable Tax Collected at Source (TCS) rules, and all reporting requirements, including Schedule FA in your income-tax return.

Do I need the price of a whole IMCR share to invest?

Yes. You can buy fractional shares, which lets you invest a fixed rupee/dollar amount even in high-priced stocks. For example, if one share trades at USD 1,000 and you invest USD 100, you receive 0.1 of a share.

How much can I invest in US stocks in a year?

Under the LRS, an Indian resident can remit up to USD 250,000 per financial year (April to March) across all permitted purposes combined, from their own funds. This is a per-individual limit set by the RBI.

Can I trade IMCR options or futures?

No. Under RBI / FEMA rules, the LRS does not permit margin trading or speculative instruments such as futures, options, or other derivatives. Your US account is a cash account, not a derivatives and margin account.

Insights

Quotes run fifteen minutes behind.

Below its 50- and 200-day averages
The 4 Nov 2026 close of $29.23 was 8.5% below its 50-day average ($31.93) and 7.8% below its 200-day average ($31.71). It has closed below the 200-day for 5 sessions, since 29 Oct 2026. The 50-day average crossed above the 200-day on 20 Aug 2026, 53 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
Behind SPY and its sector fund XLV over 1 year
1 month: −1.1% (SPY −1.6%, XLV +13.5%). 3 months: −12.2% (SPY −0.4%, XLV +15.5%). 1 year: −8.4% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: IMCR, SPY and XLV · as of 4 Nov 2026
15.7 days to cover short interest
7.8M shares were sold short at the 15 Oct 2026 settlement, 15.1% of the 51.5M shares outstanding; covering them would take 15.7 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
6.3% above its 52-week low
Closed at $29.23 on 4 Nov 2026: 28.2% below the 52-week high of $40.71 (5 Dec 2025) and 6.3% above the low of $27.50 (14 Oct 2026).
Daily price bars, split-adjusted · as of 4 Nov 2026
Volume 2.8× its 30-session average on 29 Oct 2026
29 Oct 2026 volume of 1.3M shares was 2.8× the average of the 30 sessions before it (465.0K), as the price fell 4.1%. SPY traded 1.0× its own average that session.
Daily volume against a 30-session baseline · as of 29 Oct 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month−1.1%

6 months−4.9%

1 year−8.4%

5 years−24.5%

Newswire

About

Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.

Website

Notable moves

September 9, 2022
−22.09%
September 8, 2022
+14.93%
May 13, 2022
+13.59%

Newswire

About

Website

Notable moves

September 9, 2022
−22.09%
September 8, 2022
+14.93%
May 13, 2022
+13.59%

Immunocore Holdings plc

XNASHealth care

Last traded price · USD

$29.23

+0.00%Delayed · Pre-market

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 16:00 IST · A quote does not mean the product is available to trade on your account.

Day's open: —
Previous close: $29.23
Volume: —
Day's high: —
Day's low: —

In brief

Immunocore Holdings plc is a health care company listed on Nasdaq, valued at about $1.51B.
Its shares closed at $29.23 on 4 Nov 2026, down 8.4% over the past year.
From India you can buy IMCR in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy Immunocore Holdings plc (IMCR) shares from India?

Do I need the price of a whole IMCR share to invest?

How much can I invest in US stocks in a year?

Can I trade IMCR options or futures?

Insights

Quotes run fifteen minutes behind.

Below its 50- and 200-day averages
The 4 Nov 2026 close of $29.23 was 8.5% below its 50-day average ($31.93) and 7.8% below its 200-day average ($31.71). It has closed below the 200-day for 5 sessions, since 29 Oct 2026. The 50-day average crossed above the 200-day on 20 Aug 2026, 53 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
Behind SPY and its sector fund XLV over 1 year
1 month: −1.1% (SPY −1.6%, XLV +13.5%). 3 months: −12.2% (SPY −0.4%, XLV +15.5%). 1 year: −8.4% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: IMCR, SPY and XLV · as of 4 Nov 2026
15.7 days to cover short interest
7.8M shares were sold short at the 15 Oct 2026 settlement, 15.1% of the 51.5M shares outstanding; covering them would take 15.7 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
6.3% above its 52-week low
Closed at $29.23 on 4 Nov 2026: 28.2% below the 52-week high of $40.71 (5 Dec 2025) and 6.3% above the low of $27.50 (14 Oct 2026).
Daily price bars, split-adjusted · as of 4 Nov 2026
Volume 2.8× its 30-session average on 29 Oct 2026
29 Oct 2026 volume of 1.3M shares was 2.8× the average of the 30 sessions before it (465.0K), as the price fell 4.1%. SPY traded 1.0× its own average that session.
Daily volume against a 30-session baseline · as of 29 Oct 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month−1.1%

6 months−4.9%

1 year−8.4%

5 years−24.5%

Newswire

About

Website

Notable moves

September 9, 2022
−22.09%
September 8, 2022
+14.93%
May 13, 2022
+13.59%

Newswire

About

Website

Notable moves

September 9, 2022
−22.09%
September 8, 2022
+14.93%
May 13, 2022
+13.59%

Immunocore Holdings plc

Immunocore Holdings plc in brief

Below its 50- and 200-day averages

Behind SPY and its sector fund XLV over 1 year

15.7 days to cover short interest

6.3% above its 52-week low

Volume 2.8× its 30-session average on 29 Oct 2026

Immunocore Holdings plc

Immunocore Holdings plc in brief

Below its 50- and 200-day averages

Behind SPY and its sector fund XLV over 1 year

15.7 days to cover short interest

6.3% above its 52-week low

Volume 2.8× its 30-session average on 29 Oct 2026